Abstract
The metabolic syndrome (MetS) is associated with a higher risk for both, type 2 diabetes mellitus and cardiovascular disease. The cornerstone of treatment is lifestyle modification, encompassing weight reduction and physical exercise. However, pharmacotherapy is usually also required to achieve the recommended target values for the various components of the MetS, such as hypertension, dysglycemia and dyslipidemia. Regarding lipid treatment, statins are the main therapeutic agents while in blood pressure control a significant amount of pathophysiological and clinical evidence would suggest the use, as first line agents, of ACE inhibitors or angiotensin receptor blockers. Metformin seems to be the drug of choice for dysglycemia, specially since recent evidence questions the safety of thiazolidinediones. New drugs, targeting multiple components of the MetS, are under development but no data are currently available regarding their long-term efficacy and safety profile. In general, a multifactorial approach is recommended to decrease cardiovascular risk in patients with the MetS.
Keywords: Dysglycemia, dyslipidemia, hypertension, hyperuricemia, metabolic syndrome, smoking.
Current Pharmaceutical Design
Title:Pharmacologic Therapy for Cardiovascular Risk Reduction in Patients with the Metabolic Syndrome
Volume: 20 Issue: 31
Author(s): Ioanna Gouni-Berthold and Heiner K. Berthold
Affiliation:
Keywords: Dysglycemia, dyslipidemia, hypertension, hyperuricemia, metabolic syndrome, smoking.
Abstract: The metabolic syndrome (MetS) is associated with a higher risk for both, type 2 diabetes mellitus and cardiovascular disease. The cornerstone of treatment is lifestyle modification, encompassing weight reduction and physical exercise. However, pharmacotherapy is usually also required to achieve the recommended target values for the various components of the MetS, such as hypertension, dysglycemia and dyslipidemia. Regarding lipid treatment, statins are the main therapeutic agents while in blood pressure control a significant amount of pathophysiological and clinical evidence would suggest the use, as first line agents, of ACE inhibitors or angiotensin receptor blockers. Metformin seems to be the drug of choice for dysglycemia, specially since recent evidence questions the safety of thiazolidinediones. New drugs, targeting multiple components of the MetS, are under development but no data are currently available regarding their long-term efficacy and safety profile. In general, a multifactorial approach is recommended to decrease cardiovascular risk in patients with the MetS.
Export Options
About this article
Cite this article as:
Gouni-Berthold Ioanna and Berthold K. Heiner, Pharmacologic Therapy for Cardiovascular Risk Reduction in Patients with the Metabolic Syndrome, Current Pharmaceutical Design 2014; 20 (31) . https://dx.doi.org/10.2174/1381612819666131206111721
DOI https://dx.doi.org/10.2174/1381612819666131206111721 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacotherapy of Mixed Dyslipidemia in the Metabolic Syndrome
Current Clinical Pharmacology Biologic Therapy in Inflammatory and Immunomediated Skin Diseases: Safety Profile
Current Drug Safety Natural Agents Modulating ACE-2: A Review of Compounds with Potential against SARS-CoV-2 Infections
Current Pharmaceutical Design Treatment Considerations of Clinical Physician on Hypertension Management in Asia
Current Hypertension Reviews Cross-talk Between Exogenous Statins and Endogenous High-Density Lipoprotein in Anti-Inflammatory and Anti-Atherogenic Actions
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Developments in the Search for Biomarkers for the Diagnosis and Monitoring of Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Non-Vitamin K Oral Anticoagulant Drugs for Stroke Prevention in Patients with Atrial Fibrillation and Chronic Kidney Disease
Current Medicinal Chemistry Proteochemometrics for the Prediction of Binding to the MHC Proteins
Letters in Drug Design & Discovery A Systematic Review on Synthetic Drugs and Phytopharmaceuticals Used to Manage Diabetes
Current Diabetes Reviews Atherogenesis in Renal Patients: A Model of Vascular Disease?
Current Vascular Pharmacology A Comparative Study of Short Term Efficacy of Aripiprazole and Risperidone in Schizophrenia
Current Neuropharmacology Current Evidence and Future Perspectives on Anti-platelet and Statin Pharmacotherapy for Patients with Symptomatic Peripheral Arterial Disease
Current Vascular Pharmacology Clopidogrel and Aspirin in Cardiovascular Medicine: Responders or Not -- Current Best Available Evidence
Cardiovascular & Hematological Agents in Medicinal Chemistry Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Evaluation of the Pharmacodynamic Activity of Insulin from Bilosomal Formulation
Current Drug Delivery Potential of Selected Indian Herbs for COVID-19
Current Traditional Medicine Developing Insulin and BDNF Mimetics for Diabetes Therapy
Current Topics in Medicinal Chemistry Focus on the Correlations between Alzheimer’s Disease and Type 2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets An Evidence-Based Systematic Review of Stevia by the Natural Standard Research Collaboration
Cardiovascular & Hematological Agents in Medicinal Chemistry Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design